<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1091">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707534</url>
  </required_header>
  <id_info>
    <org_study_id>12927</org_study_id>
    <nct_id>NCT04707534</nct_id>
  </id_info>
  <brief_title>Dexamethasone for COVID-19</brief_title>
  <official_title>Effects of Higher Dose and Lower Dose of Dexamethasone for Hospitalized Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label clinical trial is to evaluate two different doses of dexamethasone on the&#xD;
      health outcome using World Health Organization ordinal scale at day 28 in hospitalized&#xD;
      patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The coronavirus disease 2019 (COVID-19) pandemic is a serious global health threat. Multiple&#xD;
      antiviral or immunomodulatory therapies have failed to show any mortality benefit for&#xD;
      patients with COVID-19. Dexamethasone was shown in prior studies to improve mortality and&#xD;
      ventilator free days. However, it is unclear what dose of dexamethasone is most beneficial in&#xD;
      hospitalized patients with COVID-19. This randomized single center open label clinical trial&#xD;
      is to evaluate two different doses of dexamethasone (20mg vs. 6mg) on the health outcome for&#xD;
      hospitalized patients with COVID-19. The intervention arm is dexamethasone 20mg daily for 5&#xD;
      days, followed by dexamethasone 10mg daily for 5 days. The comparator is dexamethasone 6mg&#xD;
      daily for 10 days. Three hundred participants will be enrolled. The primary outcome is&#xD;
      clinical improvement using World Health Organization ordinal scale at day 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">June 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 21, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>World Health Organization ordinal scale at day 28</measure>
    <time_frame>28 days from study enrollment</time_frame>
    <description>1. Not hospitalized, no limitations on activities 2. Not hospitalized, limitation on activities 3. Hospitalized, not requiring supplemental oxygen 4. Hospitalized, requiring supplemental oxygen by mask or nasal prongs 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices 6. Hospitalized, on invasive mechanical ventilation 7. Hospitalized, on invasive mechanical ventilation + additional organ support (pressors, RRT, ECMO) 8. Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28 days from study enrollment</time_frame>
    <description>Days being alive and free from mechanical ventilation at day 28 after enrollment. For patients who die, it is 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>28 days from study enrollment</time_frame>
    <description>All-cause mortality at 28 days after enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Dexamethasone 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone 20 mg daily for 5 days, followed by dexamethasone 10 mg daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexamethasone 6 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone 6 mg daily for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone</description>
    <arm_group_label>Dexamethasone 20 mg</arm_group_label>
    <arm_group_label>Dexamethasone 6 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years old&#xD;
&#xD;
          -  RT-PCR confirmed COVID-19 infection&#xD;
&#xD;
          -  Positive pressure ventilation (non-invasive or invasive) or high flow nasal cannula&#xD;
             (HFNC) or need supplemental oxygen with oxygen mask or nasal cannula&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Underlying disease requiring chronic corticosteroids&#xD;
&#xD;
          -  Severe adverse events before admission, i.e. cardiac arrest;&#xD;
&#xD;
          -  Contraindication for corticosteroids;&#xD;
&#xD;
          -  Death is deemed to be imminent and inevitable during the next 24 hours&#xD;
&#xD;
          -  Recruited in other clinical intervention trial&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patient on judicial protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huimin Wu, MD MPH</last_name>
    <phone>(405) 271-6173</phone>
    <email>Huimin-Wu@ouhsc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Oklahoma Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huimin Wu, MD MPH</last_name>
      <phone>405-271-6173</phone>
      <email>huimin-wu@ouhsc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 11, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID 19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

